S&P 500   3,392.90 (+0.67%)
DOW   29,407.30 (+0.60%)
QQQ   237.44 (+1.15%)
AAPL   324.07 (+1.59%)
FB   217.99 (+0.09%)
MSFT   187.52 (+0.15%)
AMZN   2,184.74 (+1.35%)
CGC   21.87 (-0.32%)
NVDA   312.09 (+5.23%)
BABA   223.10 (+1.17%)
GE   12.71 (-0.31%)
TSLA   918.79 (+7.04%)
AMD   59.02 (+3.74%)
T   38.54 (+0.71%)
ACB   1.71 (+4.28%)
NFLX   387.40 (-0.10%)
BAC   34.83 (+1.63%)
DIS   141.68 (+1.83%)
S&P 500   3,392.90 (+0.67%)
DOW   29,407.30 (+0.60%)
QQQ   237.44 (+1.15%)
AAPL   324.07 (+1.59%)
FB   217.99 (+0.09%)
MSFT   187.52 (+0.15%)
AMZN   2,184.74 (+1.35%)
CGC   21.87 (-0.32%)
NVDA   312.09 (+5.23%)
BABA   223.10 (+1.17%)
GE   12.71 (-0.31%)
TSLA   918.79 (+7.04%)
AMD   59.02 (+3.74%)
T   38.54 (+0.71%)
ACB   1.71 (+4.28%)
NFLX   387.40 (-0.10%)
BAC   34.83 (+1.63%)
DIS   141.68 (+1.83%)
S&P 500   3,392.90 (+0.67%)
DOW   29,407.30 (+0.60%)
QQQ   237.44 (+1.15%)
AAPL   324.07 (+1.59%)
FB   217.99 (+0.09%)
MSFT   187.52 (+0.15%)
AMZN   2,184.74 (+1.35%)
CGC   21.87 (-0.32%)
NVDA   312.09 (+5.23%)
BABA   223.10 (+1.17%)
GE   12.71 (-0.31%)
TSLA   918.79 (+7.04%)
AMD   59.02 (+3.74%)
T   38.54 (+0.71%)
ACB   1.71 (+4.28%)
NFLX   387.40 (-0.10%)
BAC   34.83 (+1.63%)
DIS   141.68 (+1.83%)
S&P 500   3,392.90 (+0.67%)
DOW   29,407.30 (+0.60%)
QQQ   237.44 (+1.15%)
AAPL   324.07 (+1.59%)
FB   217.99 (+0.09%)
MSFT   187.52 (+0.15%)
AMZN   2,184.74 (+1.35%)
CGC   21.87 (-0.32%)
NVDA   312.09 (+5.23%)
BABA   223.10 (+1.17%)
GE   12.71 (-0.31%)
TSLA   918.79 (+7.04%)
AMD   59.02 (+3.74%)
T   38.54 (+0.71%)
ACB   1.71 (+4.28%)
NFLX   387.40 (-0.10%)
BAC   34.83 (+1.63%)
DIS   141.68 (+1.83%)
Log in

OTCMKTS:ENOB - Enochian Biosciences Stock Price, Forecast & News

$3.70
-0.21 (-5.37 %)
(As of 02/19/2020 02:51 PM ET)
Today's Range
$3.48
Now: $3.70
$3.90
50-Day Range
$3.68
MA: $4.60
$5.41
52-Week Range
$2.91
Now: $3.70
$7.80
Volume30,244 shs
Average Volume48,256 shs
Market Capitalization$171.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ENOB
CUSIPN/A
CIKN/A
Phone510-203-4857

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$171.34 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for ENOB and its competitors with MarketBeat's FREE daily newsletter.


Enochian Biosciences (OTCMKTS:ENOB) Frequently Asked Questions

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the OTCMKTS under the ticker symbol "ENOB."

Has Enochian Biosciences been receiving favorable news coverage?

Media coverage about ENOB stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enochian Biosciences earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for Enochian Biosciences.

Who are some of Enochian Biosciences' key competitors?

What other stocks do shareholders of Enochian Biosciences own?

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (0.13%), Charles Schwab Investment Management Inc. (0.08%), Bank of New York Mellon Corp (0.05%), UBS Group AG (0.04%), Barclays PLC (0.03%) and Renaissance Technologies LLC (0.02%). Company insiders that own Enochian Biosciences stock include Henrik Gronfeldt-Sorensen and Rene Sindlev. View Institutional Ownership Trends for Enochian Biosciences.

Which institutional investors are buying Enochian Biosciences stock?

ENOB stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., UBS Group AG, Barclays PLC, Renaissance Technologies LLC, Tower Research Capital LLC TRC and American International Group Inc.. Company insiders that have bought Enochian Biosciences stock in the last two years include Henrik Gronfeldt-Sorensen and Rene Sindlev. View Insider Buying and Selling for Enochian Biosciences.

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $3.65.

How big of a company is Enochian Biosciences?

Enochian Biosciences has a market capitalization of $168.80 million. View Additional Information About Enochian Biosciences.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is http://www.enochianbio.com/.

How can I contact Enochian Biosciences?

The company can be reached via phone at 510-203-4857.


MarketBeat Community Rating for Enochian Biosciences (OTCMKTS ENOB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Enochian Biosciences and other stocks. Vote "Outperform" if you believe ENOB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENOB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel